Raymond James & Associates’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Raymond James & Associates’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-42,620	Closed	-$4K	–	3460
2016 Q3	$4K	Hold	42,620	–	–	﹤0.01%	3193
2016 Q2	$16K	Buy	42,620 +1,000	+2%	+$380	﹤0.01%	2949
2016 Q1	$16K	Buy	+41,620	New	+$17.1K	﹤0.01%	2871

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Raymond James & Associates's PVCT Position: Q4 2016 in Review

Raymond James & Associates sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 42,620 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in PVCT in Q1 2016 and held it in 3 quarters. The position peaked at $16K in Q2 2016. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Raymond James & Associates reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Raymond James & Associates sold 42,620 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $4K.
Raymond James & Associates first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q1 2016 and held it in 3 quarters.
Raymond James & Associates's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $16K in Q2 2016.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.